Vaccine Development Services
Brain tumors, especially malignant, glioblastoma multiforme and diffuse glioma, have a very poor prognosis and are difficult to remove even with surgery, and the efficacy of radiation therapy combined with targeted therapy and chemotherapy after surgery is not very promising. Mutations in the tumor genome often result in protein changes typical of cancer, and vaccines can help the body fight the tumor by alerting the patient's immune system to these mutated proteins. Brain cancer vaccines also work by allowing the immune system to produce antibodies that can attack cancer cells.
Our vaccines development services for brain tumors
Vaccines have a place in immunotherapy as promising immunotherapeutic approaches against a variety of tumors and deserve attention in the treatment of glioblastoma and other high-grade brain tumors. Alfa Cytology aims to use the patient's immune system to find and destroy brain tumor cells or to help activate the immune system through the patient's dendritic cells (DC) to fight cancer. We hope that vaccine will carry specific antigenic information extracted from post-operative tumor tissue and deliver it to T cells after injection to stimulate tumor-killing activity. Thus, we can achieve your desired goal of prolonging the patient's survival and improving the quality of life.
We are actively trying many different strategies to develop vaccines. Vaccines prepared by transferring DNA from tumors into highly immunogenic cell lines include arrays of tumor antigens that characterize the patient's tumor. These vaccines will produce enhanced anti-tumor immune responses in mice and patients with intracerebral tumors involving the central nervous system.
Anti-brain tumor peptide vaccines
We offer peptide vaccine development services for the treatment and prevention of brain tumors, especially for the prevention of brain tumor metastasis, and offer pharmaceutical compositions comprising peptide vaccines. Our peptide vaccine development program for brain tumors includes single-target vaccines, multi-target combination vaccines, and individualized vaccines.
Dendritic cell vaccines
We aim to provide our clients with DC vaccine development services for brain tumors by rigorously considering vaccine source, vaccine antigen and adjuvant selection, vaccine targeting optimization, mobility restriction, and combination therapy. We help our customers combine with other immunotherapeutic approaches by optimizing the targeting and antigen loading of DCs and overcoming migration limitations.
The ultimate goal of treatment is to eliminate all remaining brain tumor cells in the patient's body, and a single form of therapy is unlikely to achieve this goal. The idea of vaccines is to help the immune system fight tumors by directing it to recognize protein mutations in cancer cells. Alfa Cytology is actively promoting vaccines in combination with surgery, radiotherapy, and chemotherapy as a new and important means of treating brain tumors. Please feel free to contact us to further your research and to develop and optimize vaccine treatment strategies.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
